Ferring Pharmaceuticals

13 PBAC submissions on file, active 2010–2022. 77% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Human menopausal gonadotrophin
  Women's health · Recommended · 2022—
• Degarelix
  Oncology · Recommended with restriction · 2017—
• Mesalazine
  Gastroenterology · Recommended · 2020other sponsor
• Budesonide
  Gastroenterology · Recommended · 2024other sponsor
• Follitropin delta
  Women's health · Recommended with restriction · 2017—
• Gonadotrophin-menopausal human (highly purified human menopausal gonadotrophin, hp-hmg)
  Women's health · Not recommended · 2016—
• Progesterone
  Women's health · Recommended with restriction · 2024other sponsor
• Testosterone
  Women's health · Not recommended · 2025other sponsor
• Triptorelin acetate
  Women's health · Recommended with restriction · 2016—

Therapy area mix

Activity by year

2010 (1) · 2012 (1) · 2014 (2) · 2016 (3) · 2017 (3) · 2018 (1) · 2020 (1) · 2022 (1)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×clinical data did not support a claim of non-inferior effectiveness against budesonide foam enemas
• 1×unreliable indirect comparison due to transitivity issues (extent of anatomical disease
• 1×concomitant 5-ASA use
• 1×timing of trial assessment)
• 1×different placebo response rates across trials